TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07838740: A Phase 1 Study of VK2735 in Obese Adults Without Comorbidities

Sponsor: Viking Therapeutics, Inc. · Phase: PHASE1 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 270 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$7,224,320

Rescue Site Savings

+$4,763,536

Unlock Full NCT07838740 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07838740 Rescue Dossier →